585 related articles for article (PubMed ID: 18646787)
41. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.
Maegdefrau U; Amann T; Winklmeier A; Braig S; Schubert T; Weiss TS; Schardt K; Warnecke C; Hellerbrand C; Bosserhoff AK
J Pathol; 2009 Aug; 218(4):520-9. PubMed ID: 19431154
[TBL] [Abstract][Full Text] [Related]
42. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma.
Lee NP; Leung KW; Cheung N; Lam BY; Xu MZ; Sham PC; Lau GK; Poon RT; Fan ST; Luk JM
Proteomics; 2008 May; 8(10):2136-49. PubMed ID: 18425728
[TBL] [Abstract][Full Text] [Related]
43. Proteomics for the early detection and treatment of hepatocellular carcinoma.
Feng JT; Shang S; Beretta L
Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
[TBL] [Abstract][Full Text] [Related]
44. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.
Ang IL; Poon TC; Lai PB; Chan AT; Ngai SM; Hui AY; Johnson PJ; Sung JJ
J Proteome Res; 2006 Oct; 5(10):2691-700. PubMed ID: 17022640
[TBL] [Abstract][Full Text] [Related]
45. [Correlation between serum alpha-fetoprotein variant levels in patients with hepatocellular carcinoma and the presence of alpha-fetoprotein mRNA in the circulating blood].
Kang XY; Yin ZF; Qian HH; Wu ZD; Yu ZX; Wu MC
Zhonghua Gan Zang Bing Za Zhi; 2003 Jan; 11(1):17-9. PubMed ID: 12546734
[TBL] [Abstract][Full Text] [Related]
46. [Comparative genomic classification of human hepatocellular carcinoma].
Kaposi-Novák P
Magy Onkol; 2009 Mar; 53(1):61-7. PubMed ID: 19318328
[TBL] [Abstract][Full Text] [Related]
47. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.
Xu XL; Xing BC; Han HB; Zhao W; Hu MH; Xu ZL; Li JY; Xie Y; Gu J; Wang Y; Zhang ZQ
Carcinogenesis; 2010 Feb; 31(2):167-74. PubMed ID: 19897602
[TBL] [Abstract][Full Text] [Related]
48. The targeted expression of interleukin-2 in human hepatocellular carcinoma cells.
He P; Tang ZY; Ye SL; Liu BB; Liu YK
J Exp Clin Cancer Res; 2000 Jun; 19(2):183-7. PubMed ID: 10965816
[TBL] [Abstract][Full Text] [Related]
49. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
50. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.
Murugavel KG; Mathews S; Jayanthi V; Shankar EM; Hari R; Surendran R; Vengatesan A; Raghuram K; Rajasambandam P; Murali A; Srinivas U; Palaniswamy KR; Pugazhendhi T; Thyagarajan SP
Int J Infect Dis; 2008 Nov; 12(6):e71-6. PubMed ID: 18658001
[TBL] [Abstract][Full Text] [Related]
51. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma.
Park KS; Kim H; Kim NG; Cho SY; Choi KH; Seong JK; Paik YK
Hepatology; 2002 Jun; 35(6):1459-66. PubMed ID: 12029631
[TBL] [Abstract][Full Text] [Related]
52. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.
Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Chen DS; Yu CY; Wen CL; Lu FJ; Chow LP
Proteomics; 2006 May; 6(9):2865-73. PubMed ID: 16586433
[TBL] [Abstract][Full Text] [Related]
53. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients.
Zhou SF; Xie XX; Bin YH; Lan L; Chen F; Luo GR
Clin Chim Acta; 2006 Apr; 366(1-2):274-80. PubMed ID: 16356486
[TBL] [Abstract][Full Text] [Related]
54. [Serum and tissue expressions of galectin-3 in hepatocellular carcinoma and the clinical significances].
Fang QQ; Ni RZ; Xiao MB; Jiang F; Lu CH
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):527-31. PubMed ID: 22152245
[TBL] [Abstract][Full Text] [Related]
55. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
[TBL] [Abstract][Full Text] [Related]
56. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera.
Chignard N; Shang S; Wang H; Marrero J; Bréchot C; Hanash S; Beretta L
Gastroenterology; 2006 Jun; 130(7):2010-22. PubMed ID: 16762624
[TBL] [Abstract][Full Text] [Related]
57. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Yang XR; Xu Y; Yu B; Zhou J; Li JC; Qiu SJ; Shi YH; Wang XY; Dai Z; Shi GM; Wu B; Wu LM; Yang GH; Zhang BH; Qin WX; Fan J
Clin Cancer Res; 2009 Sep; 15(17):5518-27. PubMed ID: 19706825
[TBL] [Abstract][Full Text] [Related]
58. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell.
Yang X; Zhang Y; Zhang L; Zhang L; Mao J
Cancer Lett; 2008 Nov; 271(2):281-93. PubMed ID: 18657899
[TBL] [Abstract][Full Text] [Related]
59. Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma.
Ip WK; Lai PB; Wong NL; Sy SM; Beheshti B; Squire JA; Wong N
Cancer Lett; 2007 Jun; 250(2):284-91. PubMed ID: 17126992
[TBL] [Abstract][Full Text] [Related]
60. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.
Tsunedomi R; Ogawa Y; Iizuka N; Sakamoto K; Tamesa T; Moribe T; Oka M
Int J Oncol; 2010 Jan; 36(1):205-12. PubMed ID: 19956849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
